TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00914160
Drug: Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
Normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00914160
Drug: Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03566810
Drug: Test GXR
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study: NCT03566810
Drug: Reference GXR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study: NCT03876119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm/group descriptions.
Study: NCT03386487
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator will be administered by mouth daily for eight weeks.
Study: NCT01947751
Drug: CVC maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
Study: NCT01883544
Drug: ALXN1007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02591199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02591199
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002896
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002896
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01144949
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo capsule orally, once daily, with food for up to 4 weeks
Study: NCT01631903
Drug: telepristone acetate 12 mg
Normalized name: zinc acetate 12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg, vaginal capsule, once daily for 4 months
Study: NCT01631903
Drug: telepristone acetate 12 mg
Normalized name: zinc acetate 12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg, vaginal capsule, once daily, for 3 months
Study: NCT01631903
Drug: telepristone acetate 24 mg
Normalized name: calcium acetate 5.24 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg, vaginal capsule, once daily for 4 months
Study: NCT00495469
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
Study: NCT00495469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available as Placebo matching tablet to GSK189075
Study: NCT02943655
Drug: mefenamic acid (ponstan forte)
Normalized name: Meclofenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral 500 mg mefenamic acid three times per day
Study: NCT00868231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
Study: NCT03079089
Drug: Sequential Packaging (SET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
Study: NCT03079089
Drug: Prevention of GVHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~* Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)
Study: NCT03079089
Drug: Care supports
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the protocols of each center
Study: NCT03079089
Drug: Lymphocyte injection of prophylactic donor (PDLI)
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin Injection [ATGAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II.
Study: NCT02725957
Drug: Saline 0.9% IV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06021574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00632619
Drug: Stimulant medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
Study: NCT00596830
Drug: CP-751,871 (Figitumumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
Study: NCT01278693
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg,twice daily, 16 weeks.
Study: NCT00215878
Drug: D-serine (~2g /day)
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
Study: NCT01847989
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
Study: NCT01444846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules, 0 mg ebselen, twice daily, 4 days
Study: NCT03547895
Drug: vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
Normalized name: Milk thistle
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: symptomatic therapy for liver support, control of ascites and bleeding tendency.
Study: NCT00276809
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03318016
Drug: Cyclophosphamide 500 MG
Normalized name: cyclophosphamide 500 MG
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses
Study: NCT03635333
Drug: Flavor
Normalized name: FLAVOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavor of e-juice (tobacco, menthol, strawberry)
Study: NCT04517552
Drug: [11C]-CS1P1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
Study: NCT03318016
Drug: Cyclophosphamide 1000 MG
Normalized name: cyclophosphamide 1000 MG
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study: NCT03318016
Drug: Cyclophosphamide 2000 MG
Normalized name: cyclophosphamide 2000 MG
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study: NCT03318016
Drug: Cyclophosphamide 3000 MG
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study: NCT01548209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
Study: NCT03318016
Drug: Cyclophosphamide 4000 MG
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study: NCT03083522
Drug: Ojeok-San
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT03083522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT02082236
Drug: Treatment Arm A: Sufenta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
Study: NCT02082236
Drug: Treatment B: Sufentanil SSM 30 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose SSM 30 mcg
Study: NCT01447732
Drug: CEP-37250/KHK2804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.
Study: NCT01625000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
Study: NCT02082236
Drug: Treatment C: SSM 15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 consecutive doses of SSM 15 mcg administered 20 minutes apart
Study: NCT02082236
Drug: Treatment D: SSM 30 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 consecutive doses of SSM 30 mcg administered 1 hour apart
Study: NCT01072877
Drug: Placebo Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vehicle
Study: NCT01545570
Drug: GSK2376497
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2376497 Active Comparator
Study: NCT01121120
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mcg/kg/day, administered subcutaneously for up to 28 days
Study: NCT01121120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mcg/kg/day administered subcutaneously for up to 28 days
Study: NCT02240641
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02240641
Drug: antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02240641
Drug: alpha blockers
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02240641
Drug: Angiotensin-Converting Enzyme Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00699452
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02240641
Drug: beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00352885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
Study: NCT03180970
Drug: 1.2% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Study: NCT03180970
Drug: 1.0% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Study: NCT03180970
Drug: 0.8% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Study: NCT03180970
Drug: 0.6% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Study: NCT03180970
Drug: 0.4% Lugol's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Study: NCT02658773
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03282487
Drug: Modified release hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
Study: NCT01569048
Drug: propofol and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
Study: NCT00002812
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002812
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00002812
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00002812
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00656123
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2 administered IV on Day 1 of Cycles 1-4
Study: NCT02685670
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01128946
Drug: NaF
Normalized name: Renaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
Study: NCT01128946
Drug: SnF
Normalized name: Apex 26 Lead Trasnfer Set CS4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride toothpaste containing stannous fluoride (1100 ppmF)
Study: NCT01128946
Drug: NaMFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
Study: NCT00145574
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Tablets
Study: NCT01882530
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01339897
Drug: 5 mg/N6022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous formulation, given at doses of 5 mg once each day over 7 days.
Study: NCT01339897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same administration procedures as active
Study: NCT01339897
Drug: 10mg/N6022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous formulation given at doses of 10 mg once each day over 7 days.
Study: NCT01339897
Drug: 20mg/N6022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous formulation given at doses of 20 mg once each day over 7 days.
Study: NCT01884272
Drug: naproxen 250 mg
Normalized name: naproxen 250 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01884272
Drug: indomethacin 25 mg
Normalized name: indomethacin 25 MG
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03657095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
Study: NCT04202887
Drug: Low Dose Fentanyl
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
Study: NCT04202887
Drug: High Dose Fentanyl
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
Study: NCT00762658
Drug: AN2728 Ointment, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762658
Drug: AN2728 Ointment, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762658
Drug: AN2728 Ointment, 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762658
Drug: AN2728 Ointment Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762658
Drug: Betnesol®-V Creme, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762658
Drug: Protopic® Ointment, 0.1 %
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01438021
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intraventricularly
Study: NCT01380834
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
Study: NCT01380834
Drug: treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
Study: NCT03214406
Drug: Arm & Hammer Advance White Brilliant Sparkle (Test product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sodium bicarbonate
Study: NCT00492336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet each day
Study: NCT04103697
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2, bid, per os, days 1-14, 4 cycles
Study: NCT04103697
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study: NCT00647751
Drug: Lamictal® Tablets 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x25mg, single dose fed
Study: NCT02106520
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04623814
Drug: HEC113995
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
Study: NCT04623814
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered fasted or with food for 10 days.
Study: NCT04408261
Drug: Buqitongluo Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
Study: NCT04408261
Drug: Buqitongluo Granule Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
Study: NCT00647673
Drug: Verelan® PM Extended-Release Capsules 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg, single dose fasting
Study: NCT00066027
Drug: 20 mg doxycycline hyclate
Normalized name: doxycycline hyclate 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
Study: NCT00066027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the placebo group took a placebo look-alike twice daily for two years.
Study: NCT02680756
Drug: Ferric Carboxy Maltose
Normalized name: Maltose
DrugBank: Maltose (DB03323)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00182520
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 - 400 mg/day x 12 weeks
Study: NCT04371718
Drug: JKB-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
Study: NCT00073970
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg, given twice daily
Study: NCT03681691
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal 17β-estradiol patch
Study: NCT00465985
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00465985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02752646
Drug: nepafenac 0.3%
Normalized name: NEPAFENAC 0.3% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
Study: NCT02752646
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.